Congress Asset Management Co Q3 2026 Investment Activity Analysis

As part of our ongoing analysis of institutional investor activity, we examine the quarterly investment changes of Congress Asset Management Co. The period ending September 30, 2026, shows a dynamic portfolio with strategic buying and selling across various sectors. The total portfolio value stood at $15.4 billion, with the firm making notable adjustments to its holdings.

In the Technology sector, Congress Asset Management Co demonstrated active buying, particularly in Halozyme Therapeutics Inc (HALO), which saw an 85.63% increase in its portfolio allocation to 1.63%. Similarly, APH (APH) increased by 75.9% to a 1.17% allocation, while the firm initiated a new position in MQ (MQ) with a 0.05% allocation. These purchases suggest confidence in the sector's growth potential.

Healthcare investments also featured prominently, with the firm adding positions to MettLife Sciences Inc (MDT) and Amarin Corp Ltd (AMRX), both new additions at 0.49% and 0.2% respectively. Additionally, Halozyme Therapeutics Inc (HALO) and Rogenomics Inc (RGEN) were bought, increasing their allocations to 1.63% and 0.2%. These moves indicate a strategic focus on therapeutic advancements and pharmaceutical innovation.

Consumer Cyclical holdings saw significant reduction, with ORLY (ORLY) and VIK (VIK) being sold. ORLY's allocation dropped by 81.54% to 0.15%, while UBER (UBER) was completely exited. The firm also sold VIK (VIK), which was previously a small holding. These exits might signal a shift in consumer trends or outlook for these companies.

Other sectors showed varied activity. In Industrials, the firm sold MIR (MIR) holdings, reducing its stake by 99.68% to 0.0%. Financial Services and others also saw exits, including TKO (TKO) and ORLY (ORLY) which was sold in multiple sectors. These actions reflect a broader pattern of divesting certain stocks.

Overall, the quarter highlights Congress Asset Management Co's selective approach to investing. The firm focused on acquiring companies like Halozyme Therapeutics Inc, APH, MettLife Sciences Inc, and others, while strategically reducing exposure in declining sectors. This analysis provides a snapshot of the firm's investment priorities during Q3 2026.